Literature DB >> 22136817

Molecular pathways associated with mortality in papillary thyroid cancer.

Naris Nilubol1, Chotiya Sukchotrat, Lisa Zhang, Mei He, Electron Kebebew.   

Abstract

BACKGROUND: A better understanding of the molecular mechanisms involved in papillary thyroid cancer (PTC)-associated adverse outcome is needed to manage these patients effectively. Our objectives were to identify molecular pathways associated with unfavorable features and outcomes in patients with PTC.
METHODS: We performed genome-wide expression (GWE) analysis in 64 human tissue samples affected by PTC. Clinical, pathologic, and microarray data were analyzed to identify differentially expressed genes and pathways associated with unfavorable outcomes. Gene set enrichment analysis (GSEA) was used to determine which molecular pathways are associated with mortality.
RESULTS: GWE analysis identified 43, 115, and 40 genes that were significantly differentially expressed by gender, tumor differentiation status, and mortality, respectively, with a false-discovery rate of <5%. For mortality, GSEA revealed 7 enriched pathways, including transfer RNA synthesis, mitochondria and oxidative phosphorylation, porphyrin and chlorophyll metabolism, and fatty acid synthesis. Leading-edge analysis showed that 341 genes were significantly involved in the enriched pathways. Cluster analysis using 100 differentially expressed genes showed complete separation of patients by mortality.
CONCLUSION: To our knowledge, this is the first GWE analysis of PTC and adverse outcomes. We found 11 molecular pathways that were significantly associated with mortality resulting from PTC. A 100-gene signature completely separates patients with and without PTC-associated mortality. Published by Mosby, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22136817      PMCID: PMC5581404          DOI: 10.1016/j.surg.2011.09.021

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  24 in total

Review 1.  The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies.

Authors:  T G Willis; M J Dyer
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

2.  Deregulation of Aurora kinase gene expression in human testicular germ cell tumours.

Authors:  E Baldini; Y Arlot-Bonnemains; M Mottolese; S Sentinelli; B Antoniani; S Sorrenti; M Salducci; E Comini; S Ulisse; M D'Armiento
Journal:  Andrologia       Date:  2010-08       Impact factor: 2.775

3.  Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.

Authors:  Annette Wunderlich; Melina Fischer; Torsten Schlosshauer; Annette Ramaswamy; Brandon H Greene; Cornelia Brendel; Dietrich Doll; Detlef Bartsch; Sebastian Hoffmann
Journal:  Cancer Sci       Date:  2011-02-17       Impact factor: 6.716

4.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

5.  Analysis of the expression of Fas, FasL and Bcl-2 in the pathogenesis of autoimmune thyroid disorders.

Authors:  Shenren Chen; S M Fazle Akbar; Zhichao Zhen; Yiping Luo; Lijuan Deng; Haihua Huang; Linxin Chen; Wei Li
Journal:  Cell Mol Immunol       Date:  2004-06       Impact factor: 11.530

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer.

Authors:  Arezo Ghanipour; Karin Jirström; Fredrik Pontén; Bengt Glimelius; Lars Påhlman; Helgi Birgisson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-11       Impact factor: 4.254

8.  The tumor suppressor Cdc73 functionally associates with CPSF and CstF 3' mRNA processing factors.

Authors:  Orit Rozenblatt-Rosen; Takashi Nagaike; Joshua M Francis; Syuzo Kaneko; Karen A Glatt; Christina M Hughes; Thomas LaFramboise; James L Manley; Matthew Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-09       Impact factor: 11.205

9.  Two-site phosphorylation of EPRS coordinates multimodal regulation of noncanonical translational control activity.

Authors:  Abul Arif; Jie Jia; Rupak Mukhopadhyay; Belinda Willard; Michael Kinter; Paul L Fox
Journal:  Mol Cell       Date:  2009-07-31       Impact factor: 17.970

10.  Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers.

Authors:  Hussain Almubarak; Antonia Jones; Risa Chaisuparat; Ming Zhang; Timothy F Meiller; Mark A Scheper
Journal:  J Carcinog       Date:  2011-01-15
View more
  7 in total

1.  Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease.

Authors:  Naris Nilubol; Myriem Boufraqech; Lisa Zhang; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2014-03-21       Impact factor: 5.958

2.  Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma.

Authors:  Shih-Ping Cheng; Ming-Jen Chen; Ming-Nan Chien; Chi-Hsin Lin; Jie-Jen Lee; Chien-Liang Liu
Journal:  Clin Exp Med       Date:  2016-12-21       Impact factor: 3.984

3.  Multicompartment metabolism in papillary thyroid cancer.

Authors:  Patrick Tassone; Joseph M Curry; Paolo Cotzia; John Sprandio; Adam Luginbuhl; David M Cognetti; Mehri Mollaee; Marina Domingo; Edmund A Pribitkin; William M Keane; Ting Ting Zhan; Ruth Birbe; Madalina Tuluc; Ubaldo Martinez-Outschoorn
Journal:  Laryngoscope       Date:  2015-12-15       Impact factor: 3.325

4.  Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases.

Authors:  Dilmi Perera; Ronald Ghossein; Niedzica Camacho; Yasin Senbabaoglu; Venkatraman Seshan; Juan Li; Nancy Bouvier; Laura Boucai; Agnes Viale; Nicholas D Socci; Brian R Untch; Mithat Gonen; Jeffrey Knauf; James A Fagin; Michael Berger; R Michael Tuttle
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 6.134

5.  Integrated microRNA, gene expression and transcription factors signature in papillary thyroid cancer with lymph node metastasis.

Authors:  Nurul-Syakima Ab Mutalib; Sri Noraima Othman; Azliana Mohamad Yusof; Shahrun Niza Abdullah Suhaimi; Rohaizak Muhammad; Rahman Jamal
Journal:  PeerJ       Date:  2016-06-15       Impact factor: 2.984

6.  Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes.

Authors:  J Jonklaas; Srk Murthy; D Liu; J Klubo-Gwiezdzinska; J Krishnan; K D Burman; L Boyle; N Carrol; E Felger; Y P Loh
Journal:  Future Sci OA       Date:  2017-09-22

7.  Integrin β4 promotes invasion and anoikis resistance of papillary thyroid carcinoma and is consistently overexpressed in lymphovascular tumor thrombus.

Authors:  Jian Li; Minghua Luo; Huiting Ou; Xiaoling Liu; Xueling Kang; Weihua Yin
Journal:  J Cancer       Date:  2019-10-21       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.